Czech National Bank Raises Stake in Zoetis Inc. (NYSE:ZTS)

Czech National Bank lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 92,291 shares of the company’s stock after buying an additional 5,339 shares during the period. Czech National Bank’s holdings in Zoetis were worth $18,032,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Asset Dedication LLC lifted its stake in shares of Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock worth $204,000 after purchasing an additional 54 shares in the last quarter. Forza Wealth Management LLC grew its stake in shares of Zoetis by 1.8% in the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after buying an additional 58 shares in the last quarter. L. Roy Papp & Associates LLP lifted its position in Zoetis by 2.8% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after acquiring an additional 60 shares in the last quarter. Angeles Wealth Management LLC boosted its holdings in Zoetis by 3.8% in the 1st quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock worth $288,000 after acquiring an additional 62 shares during the period. Finally, Edge Capital Group LLC grew its position in Zoetis by 3.7% in the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after acquiring an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ZTS shares. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upped their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Down 0.5 %

NYSE ZTS traded down $0.96 on Friday, hitting $190.03. 1,421,979 shares of the stock traded hands, compared to its average volume of 2,576,563. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a 50-day moving average of $187.30 and a 200 day moving average of $175.45. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market capitalization of $86.09 billion, a P/E ratio of 36.61, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period last year, the business posted $1.41 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.